Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature

Abstract Background HER2 is a member of the ERBB family of receptor tyrosine kinases, and HER2 mutations occur in 1–4% of non-small cell lung cancer (NSCLC) as an oncogenic driver mutation. We found a rare mutation of HER2 p.Asp769Tyr in NSCLC. Case presentation We presented a case of a 68-year-old...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Huanhuan Xu, Qi Liang, Xian Xu, Shanyue Tan, Sumeng Wang, Yiqian Liu, Lingxiang Liu
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Afatinib Anlotinib HER2 mutation Lung adenocarcinoma Targeted therapy Surgery RD1-811 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/d93f651f018a4241a32241d207e7578e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d93f651f018a4241a32241d207e7578e
record_format	dspace
spelling	oai:doaj.org-article:d93f651f018a4241a32241d207e7578e2021-11-21T12:33:42ZAfatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature10.1186/s12957-021-02444-71477-7819https://doaj.org/article/d93f651f018a4241a32241d207e7578e2021-11-01T00:00:00Zhttps://doi.org/10.1186/s12957-021-02444-7https://doaj.org/toc/1477-7819Abstract Background HER2 is a member of the ERBB family of receptor tyrosine kinases, and HER2 mutations occur in 1–4% of non-small cell lung cancer (NSCLC) as an oncogenic driver mutation. We found a rare mutation of HER2 p.Asp769Tyr in NSCLC. Case presentation We presented a case of a 68-year-old nonsmoking male patient with brain metastasis from lung adenocarcinoma harboring a rare mutation of HER2 p.Asp769Tyr. After multiple lines of treatment, he obtained a durable response (10 months) to afatinib and anlotinib. Conclusion We reported for the first time that afatinib and anlotinib have successfully treated lung adenocarcinoma with HER2 p.Asp769Tyr mutation. This finding can provide an insight into the optimal treatment of lung adenocarcinoma patients with novel mutations. Additionally, we summarized the efficacy of targeted therapy for HER2 mutant lung cancer in this article.Huanhuan XuQi LiangXian XuShanyue TanSumeng WangYiqian LiuLingxiang LiuBMCarticleAfatinibAnlotinibHER2 mutationLung adenocarcinomaTargeted therapySurgeryRD1-811Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENWorld Journal of Surgical Oncology, Vol 19, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Afatinib Anlotinib HER2 mutation Lung adenocarcinoma Targeted therapy Surgery RD1-811 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Afatinib Anlotinib HER2 mutation Lung adenocarcinoma Targeted therapy Surgery RD1-811 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Huanhuan Xu Qi Liang Xian Xu Shanyue Tan Sumeng Wang Yiqian Liu Lingxiang Liu Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature
description	Abstract Background HER2 is a member of the ERBB family of receptor tyrosine kinases, and HER2 mutations occur in 1–4% of non-small cell lung cancer (NSCLC) as an oncogenic driver mutation. We found a rare mutation of HER2 p.Asp769Tyr in NSCLC. Case presentation We presented a case of a 68-year-old nonsmoking male patient with brain metastasis from lung adenocarcinoma harboring a rare mutation of HER2 p.Asp769Tyr. After multiple lines of treatment, he obtained a durable response (10 months) to afatinib and anlotinib. Conclusion We reported for the first time that afatinib and anlotinib have successfully treated lung adenocarcinoma with HER2 p.Asp769Tyr mutation. This finding can provide an insight into the optimal treatment of lung adenocarcinoma patients with novel mutations. Additionally, we summarized the efficacy of targeted therapy for HER2 mutant lung cancer in this article.
format	article
author	Huanhuan Xu Qi Liang Xian Xu Shanyue Tan Sumeng Wang Yiqian Liu Lingxiang Liu
author_facet	Huanhuan Xu Qi Liang Xian Xu Shanyue Tan Sumeng Wang Yiqian Liu Lingxiang Liu
author_sort	Huanhuan Xu
title	Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature
title_short	Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature
title_full	Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature
title_fullStr	Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature
title_full_unstemmed	Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature
title_sort	afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel her2 mutation: a case report and review of the literature
publisher	BMC
publishDate	2021
url	https://doaj.org/article/d93f651f018a4241a32241d207e7578e
work_keys_str_mv	AT huanhuanxu afatinibcombinedwithanlotinibinthetreatmentoflungadenocarcinomapatientwithnovelher2mutationacasereportandreviewoftheliterature AT qiliang afatinibcombinedwithanlotinibinthetreatmentoflungadenocarcinomapatientwithnovelher2mutationacasereportandreviewoftheliterature AT xianxu afatinibcombinedwithanlotinibinthetreatmentoflungadenocarcinomapatientwithnovelher2mutationacasereportandreviewoftheliterature AT shanyuetan afatinibcombinedwithanlotinibinthetreatmentoflungadenocarcinomapatientwithnovelher2mutationacasereportandreviewoftheliterature AT sumengwang afatinibcombinedwithanlotinibinthetreatmentoflungadenocarcinomapatientwithnovelher2mutationacasereportandreviewoftheliterature AT yiqianliu afatinibcombinedwithanlotinibinthetreatmentoflungadenocarcinomapatientwithnovelher2mutationacasereportandreviewoftheliterature AT lingxiangliu afatinibcombinedwithanlotinibinthetreatmentoflungadenocarcinomapatientwithnovelher2mutationacasereportandreviewoftheliterature
_version_	1718418974425743360

Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature

Ejemplares similares